New IPO filings include BridgeBio, Dermavant, Prevail, Atreca, Akero

In a week in which two biotechs went public and a third opted for a billion-dollar takeout instead of an IPO, five companies filed on Friday to list on NASDAQ in IPOs that could raise a total of $611.3 million. The group includes BridgeBio, Dermavant, Prevail, Atreca and Akero.

BridgeBio Pharma LLC (Palo Alto, Calif.) proposed to raise up to $225 million in an IPO underwritten by J.P. Morgan, Goldman Sachs, Jefferies, SVP Leerink, KKR, Piper Jaffray, Mizuho Securities, BMO Capital Markets and Raymond James. The company in-licenses preclinical and clinical assets from academia and pharma, and houses them in individual subsidiaries. BridgeBio raised a $299.2 million venture round in January that was co-led by KKR and Viking Global Investors. Each hold a 5% stake in the biotech (see "BridgeBio Raises $299M to Advance Rare Disease Portfolio")...